Biomarker set for identifiying a severe form of cancer
Breast cancer has been recognized as a heterogeneous
disease that consists of different intrinsic subtypes, including hormone receptor positive breast cancer (also known as luminal breast cancer), which accounts for 70-80% of newly diagnosed breast tumors. The histologic grade of luminal breast cancer is often determined by semi-quantitative methods describing morphologic features related to the differentiation states of the tumor specimen, ranging from well differentiated “grade 1” tumors, through intermediate differentiation (“grade 2”) to poorly differentiated “grade 3” tumors. Breast tumors characterized as luminal “grade 3” generally respond well to chemotherapeutic treatments, whereas patients with luminal “grade 1” tumors would be overtreated. In order to make a clear-cut classification of luminal breast cancer as either “grade 1” (= low risk) or “grade 3” (= high risk) tumors, DKFZ researchers have developed a 3-protein marker set.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles

Hybrid Job Training Boosts Women’s Participation in Nepal
Globally, women’s workforce participation is about 25% lower than men’s, often due to barriers such as domestic responsibilities and cultural norms. Vocational training can increase employment opportunities, but women may…

Drying and Rewetting Cycles Boost Soil CO2 Emissions
Niigata, Japan – The amount of carbon dioxide (CO2) released by microbial decomposition of soil organic carbon on a global scale is approximately five times greater than the amount of…

Improved Treatment Method for Rare Pregnancy-Related Cancer
PORTLAND, Ore. – A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other…